REGN
What one share of Regeneron Pharmaceuticals holds
Pharmaceutical Preparations
•the extent to which the results from the research and development programs conducted by us and/or our collaborators may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval;
Regeneron Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $145.12 |
|---|---|
| Profit | $40.44 |
| Capex (buildings and equipment) | $8.60 |
| Free cash flow | $35.13 |
| Dividends | $3.54 |
| Cash and investments | $173.37 |
| Debt | $26.33 |
| Book value | $308.48 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $41.79 | $7.70 | $4.40 | $8.37 | — | $42.50 |
| 2017 | $50.67 | $10.34 | $2.35 | $8.93 | — | $57.80 |
| 2018 | $44.82 | $21.29 | $3.34 | $15.78 | — | $81.16 |
| 2019 | $57.22 | $18.46 | $3.75 | $17.46 | — | $101.55 |
| 2020 | $73.82 | $30.52 | $5.34 | $17.41 | — | $102.47 |
| 2021 | $143.24 | $71.97 | $4.92 | $58.19 | — | $177.57 |
| 2022 | $107.25 | $38.22 | $5.20 | $38.98 | — | $211.62 |
| 2023 | $115.37 | $34.77 | $6.32 | $34.08 | — | $243.42 |
| 2024 | $123.39 | $38.34 | $6.57 | $31.84 | — | $272.04 |
| 2025 | $132.07 | $41.48 | $8.27 | $37.57 | — | $298.82 |